ProCE Banner Activity

Choosing a CDK4/6 Inhibitor in the Frontline Setting for HR+/HER2- Metastatic Breast Cancer: Highlighting the Importance of Shared Decision-Making

Clinical Thought

This activity provides an expert’s commentary on considerations with available CDK4/6 inhibitors for hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer and the importance of shared decision-making with your patients.

Released: December 12, 2022

Expiration: December 11, 2023

Share

Provided by

ProCE Banner

Supporters

This activity is supported by

Lilly

Disclosure

Jeremy Force, DO 
Consultant/speaker: Nanostring, Pfizer, Prime; researcher: Exact Sciences, G1 Therapeutics, Xilis.

Additional Information

Program Medium

This program has been made available online.